Option Millionaires

[uranium-pinto-beans]

TIGR +1.8%, GBDC +1.4%
Other news:

IMGN +29.3% (top-line results from pivotal Soraya trial of mirvetuximab Soravtansine in ovarian cancer)
ATHX +19.6% (Report of Placebo-Controlled Clinical Trial Evaluating MultiStem Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine) MEIP +14.3% (MEI Pharma and Kyowa Kirin announce data from the ongoing global Phase 2 TIDAL study evaluating zandelisib as a single agent in patients with relapsed or refractory follicular lymphoma),
MOLN +13.2% (confirms retained activity of Ensovibep on the positions mutated in emerging Omicron Variant)
VXX +9% (trading higher with weakness in futures)
CYBN +7.5% (announces FDA Investigational New Drug and Institutional Review Board approvals for a co-funded Phase 2 clinical trial to treat frontline clinicians experiencing COVID-related distress)
KRYS +6.8% (announced public offering; extends volatility after closing higher by approx. +122%)
OM +5.1% (received FDA 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo Hemodialysis System)
MYPS +4% (secured exclusive rights to develop the Tetris franchise for mobile devices)
ADEX +3.6% (Griid Infrastructure to list on the NYSE through merger with Adit Edtech Acquisition Corp)
HELE +2.6% (agreed acquire Osprey Packs for $414 mln in cash)
NVAX +2.6% (volatility across vaccine stocks)
RRD +2.3% (confirms receipt of revised proposal from Chatham Asset Management)
ZLAB +1.8% (phase 3 PRIME study results for ZEJULA)
MREO +1.1% (reports interim data from ACTIVATE phase 1b/2 open label study of etigilimab anti-TIGIT antibody in combination with nivolumab in solid tumors)
PFE +1% (CDC expands COVID-19 booster recommendations)
Analyst comments:

ESMT +3.4% (upgraded to Strong Buy from Outperform at Raymond James)
KRP +0.8% (upgraded to Overweight from Equal Weight at Wells Fargo)